Cargando…

O-09: DURABLE ENGRAFTMENT AFTER PHARMACOLOGICAL PRE-TRANSPLANT IMMUNOSUPPRESSION FOLLOWED BY REDUCED-TOXICITY MYELOABLATIVE HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN HIGHLY HLA-IMMUNIZED ADULTS WITH SICKLE CELL DISEASE

Detalles Bibliográficos
Autores principales:	S., FÜRST, E., BERNIT, A., GRANATA, F., LEGRAND, S., HARBI, R., DEVILLIER, V., MAISANO, B., BOUCHACOURT, T., PAGLIARDINI, D., MOKART, C., LEMARIÉ, B., CALMELS, C., PICARD, A., BASIRE, C., CHABANNON, B., ANDERSSON, D., BLAISE
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426781/ http://dx.doi.org/10.1097/01.HS9.0000872844.05995.69

Ejemplares similares

P1332: PROMISING OUTCOME OF PATIENTS OLDER THAN 70 YEARS WHO UNDERWENT PERIPHERAL BLOOD HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC SYNDROME
por: Harbi, S., et al.
Publicado: (2022)

P1329: POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) VERSUS ANTITHYMOCYTE GLOBULIN (ATG) AS GVHD PROPHYLAXIS FOR MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION.
por: Dachy, F., et al.
Publicado: (2022)

Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic
por: Mfarrej, B., et al.
Publicado: (2021)

Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas
por: Zhenyang, Gu, et al.
Publicado: (2021)

Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning
por: Wagner, John E., et al.
Publicado: (2021)

Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome
por: Castagna, Luca, et al.
Publicado: (2020)

PB1810: OUTCOME OF ACUTE MYELOID LEUKEMIA RELAPSE AFTER ALLOGENIC STEM CELL TRANSPLANT: A SINGLE INSTITUTION RETROSPECTIVE STUDY
por: Castoldi, C., et al.
Publicado: (2022)

Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus on Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation
por: El-Cheikh, Jean, et al.
Publicado: (2013)

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
por: Solomon, Scott R., et al.
Publicado: (2016)

Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis
por: Gao, Wen-hui, et al.
Publicado: (2023)

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study
por: Popat, Uday R., et al.
Publicado: (2022)

Successful HLA haploidentical myeloablative stem cell transplantation for aggressive hepatosplenic alpha/beta (αβ) T-cell lymphoma
por: Catania, Gioacchino, et al.
Publicado: (2014)

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
por: Alvarez, Maite, et al.
Publicado: (2021)

Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease
por: Saraf, Santosh L., et al.
Publicado: (2018)

T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies
por: Katsanis, Emmanuel, et al.
Publicado: (2020)

Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients
por: Castagna, Luca, et al.
Publicado: (2020)

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor
por: Devillier, Raynier, et al.
Publicado: (2021)

Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
por: El-Cheikh, Jean, et al.
Publicado: (2015)

NK cell content does not seem to influence engraftment in ex vivo T cell depleted haploidentical stem cell transplantation
por: Merli, Pietro, et al.
Publicado: (2022)

Comparison of outcomes in hematological malignancies treated with haploidentical or HLA-identical sibling hematopoietic stem cell transplantation following myeloablative conditioning: A meta-analysis
por: Chen, Dangui, et al.
Publicado: (2018)

Manufacturing Natural Killer Cells as Medicinal Products
por: Chabannon, Christian, et al.
Publicado: (2016)

Response to NK cell content does not seem to influence engraftment in ex vivo T cell depleted haploidentical stem cell transplantation
por: Lobo de Figueiredo-Pontes, Lorena, et al.
Publicado: (2022)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

Sepax-2 cell processing device: a study assessing reproducibility of concentrating thawed hematopoietic progenitor cells
por: Mfarrej, Bechara, et al.
Publicado: (2022)

Advances in haploidentical stem cell transplantation
por: Bayraktar, Ulas Darda, et al.
Publicado: (2011)

Overview of the progress on haploidentical hematopoietic transplantation
por: Farhadfar, Nosha, et al.
Publicado: (2016)

The Evolution of T Cell Depleted Haploidentical Transplantation
por: Aversa, Franco, et al.
Publicado: (2019)

Review of Haploidentical Hematopoietic Cell Transplantation
por: Khan, Mehreen A., et al.
Publicado: (2018)

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
por: Ayoglu, Burcu, et al.
Publicado: (2023)

Combination treatment of rituximab and donor platelets infusion to reduce donor‐specific anti‐HLA antibodies for stem cells engraftment in haploidentical transplantation
por: Zhang, Rongli, et al.
Publicado: (2020)

PB2439: EARLIER ENGRAFTMENT WITHOUT INCREASE OF GVHD IN HIGHER DOSE OF CD34+ CELLS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Tan, Tran-Der, et al.
Publicado: (2023)

Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation
por: Baumeister, Susanne H. C., et al.
Publicado: (2020)

Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia
por: Thakar, Monica S., et al.
Publicado: (2017)

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
por: Nakamura, R, et al.
Publicado: (2002)

Haploidentical Hematopoietic Stem-Cell Transplantation in Adults
por: Alshemmari, Salem, et al.
Publicado: (2011)

T cell depleted haploidentical transplantation: positive selection
por: Aversa, Franco
Publicado: (2011)

Strategies in Haploidentical Stem Cell Transplantation in Adults
por: Bayraktar, Ulaş D., et al.
Publicado: (2013)

Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation
por: Treister, Nathaniel, et al.
Publicado: (2017)

Direct bone marrow HSC transplantation enhances local engraftment at the expense of systemic engraftment in NSG mice
por: Futrega, Kathryn, et al.
Publicado: (2016)

Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction
por: van Balen, Peter, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t8gtkqtnqdvl39482np1bmmd78